Response to Letter: Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience

Dose Response. 2019 Nov 22;17(4):1559325819887068. doi: 10.1177/1559325819887068. eCollection 2019 Oct-Dec.

No abstract available

Keywords: DPYD; colorectal cancer; cost-effectiveness; fluoropyrimidine; pharmacogenomics.